FGFR3 and breast cancer: As described before, the alteration frequency of FGFR3 in low-grade and/or early-stage bladder tumors was evidently higher comparatively, such that the CRG signature could perform better in the response prediction of immunotherapeutic treatment for higher-grade BC patients, especially for those with wild-type FGFR3, while only 17 BC patients with altered FGFR3 included in the GSE176307 dataset received immune therapy treatment hence, the ability of the CRG signature to predict the immunotherapeutic treatment response for BC patients with FGFR3 alterations remained to be explored.